STAT+: Europe will accelerate its review of RevMed’s drug

STAT PlusNewsletterThe Readout Europe will accelerate its review of RevMed’s drug Kailera’s GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine Chenand Andrew JosephJuly 8, 2026 Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. If you recall, a few years ago, Pfizer moved its New York headquarters from a building in Midtown to Hudson Yards. The company’s timing was lucky.Advertisement Yesterday, officials evacuated that Midtown building, which is being converted into an apartment complex, after several floors caved in and two columns buckled. Officials say the building is at risk of collapse. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech July 8, 2026 STAT Plus: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics Biotech July 7, 2026 STAT Plus: FDA approves Vera Therapeutics kidney disease treatment Advertisement The Readout July 7, 2026 STAT Plus: Compass says depression drug has long-lasting benefits Biotech July 6, 2026 STAT Plus: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms The Readout July 6, 2026 STAT Plus: Four major biotech updates to catch up on Subscriber Picks